On 1 February 2013, the FDA approved revisions to the darunavir (Prezista) tablet and oral suspension label to include paediatric use.
This included once daily dosing in treatment-naive subjects 3 to less than 18 years of age and once-daily dosing in treatment-experienced subjects 3 to less than 18 years of age with no darunavir resistance associated substitutions.
Weight-based dosing tables are included by age, weight and treatment experience.
For full details please see the full label and/or online infromation from the FDA list serve.
Source: FDA list serve. Prezista (darunavir) tablet and oral suspension: pediatric dosing. (1 February 2013).
Links to other websites are current at date of posting but not maintained.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.